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Papillary thyroid microcarcinoma: time to shift from surgery 
to active surveillance?
Sophie Leboulleux, R Michael Tuttle, Furio Pacini, Martin Schlumberger
The incidence of diﬀ erentiated thyroid cancer is increasing greatly in high-income countries. Roughly 50% of this 
increase is attributable to the identiﬁ cation of intrathyroidal papillary thyroid microcarcinomas. Since mortality 
associated with these tumours remains low and stable, the increasing diagnosis has led to concerns about 
overdiagnosis and overtreatment. Management of papillary thyroid microcarcinomas should take into account the 
reported absence of mortality when diagnosed in the absence of lymph node metastases and distant metastases, as 
shown even in recent studies promoting active surveillance; a low recurrence rate of 1–5%; and the risk of permanent 
complications from surgery that cannot be decreased to less than 1–3%, even in high-volume tertiary care centres 
with experienced surgeons. On the basis of these data, active surveillance with curative intent, in which active 
treatment is delayed until the cancer shows signs of signiﬁ cant progression to avoid side-eﬀ ects of treatment, should 
be considered in properly selected patients.
Introduction 
Papillary thyroid microcarcinomas are small thyroid 
cancers measuring 1 cm or less. Most of these tumours 
are not palpable and are identiﬁ ed either through 
pathology examination of thyroid glands removed for 
benign conditions or from imaging procedures such as 
neck ultrasonography or CT scan for another cause. 
Much less commonly, papillary thyroid microcarcinoma 
presents with palpable neck node metastases or distant 
metastases, leading to the diagnosis of a yet unknown 
papillary thyroid cancer.
Epidemiology
Occult papillary thyroid microcarcinomas at autopsy
Findings from autopsy studies have shown that occult 
papillary thyroid microcarcinomas are present in 5–36% 
of the population (table 1).1–11 In a meta-analysis of 
989  autopsies from 15 studies, the prevalence was 
11·5%.12 Occult papillary thyroid microcarcinomas are 
characterised by a very small size, with the tumour 
smaller than 1 mm in 33–79% of cases, and a high 
frequency of multifocality, which is present in 27–50% of 
cases (table 1). The prevalence of occult papillary thyroid 
microcarcinomas is higher in people older than 40 years 
than in younger people, but is not associated with either 
iodine intake or sex. The main factor aﬀ ecting the 
prevalence of these tumours is the method used for the 
autopsy analysis.9 Occult papillary thyroid micro-
carcinomas represent a major reservoir of unknown 
thyroid malignancies, which we estimate to aﬀ ect 
roughly 20 million adults in the USA and 48 million in 
Europe. Indeed, the prevalence of occult papillary 
thyroid microcarcinomas identiﬁ ed at autopsy is 
100–1000 times higher than that of clinical cancer.
Clinical papillary thyroid microcarcinomas
There has been a substantial rise in the incidence of 
thyroid cancer in developed countries during the past 
30 years.13–16 Roughly 50% of this increase is attributable 
to the identiﬁ cation of intrathyroidal papillary thyroid 
microcarcinomas, which are present in at least 10% of 
thyroid glands removed for benign thyroid diseases.15,17 
The most common presentation of thyroid cancer is a 
papillary thyroid microcarcinoma, measuring less than 
2 mm in 60% of patients, in a patient older than 
45 years.18,19 At the same time, mortality from papillary 
thyroid carcinoma remains low and stable.17
Several changes in medical practice in high-income 
countries have resulted in the increased identiﬁ cation of 
papillary thyroid microcarcinomas that were previously 
part of a large subclinical thyroid cancer reservoir. One of 
these developments is the increased detection of 
asymptomatic incidental thyroid nodules through highly 
sensitive imaging procedures, such as the widespread 
availability of neck ultrasonography that is often used for 
various neck conditions such as pain, discomfort, or any 
kind of thyroid disease, and the availability of other 
imaging procedures that are done for unrelated reasons, 
such as carotid artery doppler studies, neck MRI for 
cervical discopathy, and CT scan or ¹⁸F-ﬂ uorodeoxyglucose 
(¹⁸F-FDG) PET scans for non-thyroidal malignancies. 
Other develop ments that have led to increased 
identiﬁ cation of papillary thyroid microcarcinomas are 
the increased spatial resolution of the latest neck 
ultrasound machines, which can now detect nodules as 
small as 2 mm; the increased ability to take biopsy 
samples from very small thyroid nodules by use of 
ultrasound-guided ﬁ ne needle aspiration; and a more 
thorough histological scrutiny of thyroid specimens 
obtained at surgery for benign thyroid diseases by 
sectioning and examining the entire thyroid gland.20 
During the past three decades, a large proportion of 
thyroid cancer diagnoses—up to 60% according to results 
from a recent study21—can be accounted for by these 
diagnostic changes. The introduction of a formal 
screening programme with ultrasonography in South 
Korea resulted in an increase in diagnosis of thyroid 
cancer by 15 times within 10 years, with clear concern 
regarding its usefulness.22,23 A screening programme 
initiated in Fukushima following the Daiichi nuclear 
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power plant accident diagnosed thyroid cancer with an 
incidence 30 times higher than the national incidence in 
children and adolescents in both contaminated and non-
contaminated regions.24 Futhermore, in high-income 
countries, the increase in diagnosis of papillary thyroid 
microcarcinomas is related to the economic status of the 
patients, because economic status is associated with 
access to medical facilities through medical health 
insurance.19,25 Although ﬁ nancial incentives to track 
coding of malignancy might have contributed to the 
increase in diagnoses of thyroid cancer in the USA, this 
is not the case in France or Italy where similar increases 
in papillary thyroid microcarcinomas have been reported 
despite the absence of ﬁ nancial remuneration for thyroid 
cancer coding.13,26,27
Clinical and occult papillary thyroid microcarcinomas 
from autopsy series are distinct entities, as reﬂ ected by 
diﬀ erences in their sex ratio and size. Although clinical 
diﬀ erentiated thyroid cancer is three times more frequent 
in women than men, the prevalence of latent papillary 
thyroid microcarcinomas does not diﬀ er between men 
and women in autopsy studies (table 1).12 The size of 
papillary thyroid microcarcinomas has been shown to be 
larger in clinical studies than in autopsy studies.12 Cohort 
studies of papillary thyroid microcarcinoma include 
patients with both clinical and occult (found at surgery) 
carcinomas because there are no formal criteria to 
distinguish one from the other. However, the prognosis 
of both clinical and occult papillary thyroid 
microcarcinomas is excellent. 
Because of the high frequency of papillary thyroid 
microcarcinomas in autopsy studies and the increasing 
incidence of clinical papillary thyroid microcarcinomas, 
there is concern about overdiagnosis and overtreatment 
of lesions that would not cause any harm if left untreated. 
To minimise this problem, a working group suggested a 
change in terminology, with use of the term indolent 
lesion of epithelial origin rather than cancer.28 Some 
radiologists suggested “turn[ing] oﬀ  the ultrasound 
machines”,29 whereas others suggested that thyroid 
micro-incidentalomas should be ignored rather than 
explored.30
Natural history and prognosis 
Mortality
Mortality related to papillary thyroid microcarcinoma is 
very low, reaching up to 0·3% in clinical series that 
included patients with palpable lymph nodes and distant 
metastases at initial presentation (table 2).31–42 Furthe-
rmore, in the absence of treatment, no deaths have been 
attributed to thyroid cancer in patients undergoing active 
surveillance.43 There is no excess mortality caused by 
papillary thyroid microcarcinoma diagnosed without 
clinical lymph nodes or distant metastases.
Risk of recurrence and predictive factors for recurrence
In series with more than 250 patients, clinical recurrences 
occurred in 1–5% of patients with papillary thyroid 
microcarcinoma, irrespective of the presence of palpable 
lymph nodes at initial diagnosis (table 2).31–41 When patients 
with palpable lymph nodes were excluded, the rate of 
recurrence decreased to less than 1%.33 In a meta-analysis, 
investigators reported a recurrence rate of 0·5% (four of 
854) in patients with incidental papillary thyroid micro-
carcinoma (diagnosed on histological examination of 
thyroid specimens following thyroid surgery for non-
cancer diagnoses), compared with 7·9% (173 of 2669) 
in patients with non-incidental papillary thyroid 
microcarcinoma (diagnosed preoperatively); however, non-
incidental papillary thyroid microcarcinoma included 
tumours diagnosed on imaging undertaken for non-
thyroid reasons and those diagnosed because of clinical 
nodal metastasis, a distinct clinical entity.42
In a single-institution series of 1066 patients with 
papillary thyroid microcarcinoma, an increased risk of 
locoregional lymph node metastases at diagnosis was 
signiﬁ cantly associated with male sex, younger age 
(≤45 years), multifocal lesions, extrathyroidal extension, 
Country N Prevalence Prevalence, male Prevalence, female Size (mm) Tumour size <1 mm Multifocal tumours
Sampson et al (1974)1 USA 157 9 (5·7%) 7/99 (7·1%) 2/58 (3·5%) NA NA NA
Sobrinho-Simoes et al (1979)2 Portugal 600 39 (6·5%) 9/338 (2·7%) 30/262 (11·5%) NA NA 12/39 (30·8%)
Bondeson et al (1981)3 Sweden 500 39* (7·8%) 17/279 (6·0%) 22/221 (10·0%) NA NA* NA
Harach et al (1985)4 Finland 101 36 (35·6%) 23/53 (43·4%) 13/48 (27·1%) NA 40/52 (76·9%) 10/36 (27·8%)
Lang et al (1988)5 Germany 1020 63 (6·2%) 39/599 (6·5%) 24/421 (5·7%) NA NA 29/63 (46·0%)
Ottino et al (1989)6 Argentina 100 11 (11·0%) 8/59 (13·6%) 3/41 (7·3%) Median 2·1 6/18 (33·3%) 3/11 (27·3%)
Yamamoto et al (1990)7 Japan 408 46 (11·3%) 26/247 (10·5%) 20/161 (12·4%) Mean 1·98 23/64 (35·9%) 14/46 (30·4%)
Furmanchuk et al (1993)8 Belarus 215 19* (8·8%) 10/138 (7·2%) 9/77 (11·7%) Mean 1·7; 
median 1·1
13/28 (46·4%) 6/19 (31·6%)
Martinez-Tello et al (1993)9 Spain 100 22 (22·0%) 16/66 (24·2%) 6/34 (17·6%) NA 42/53 (79·2%) 11/22 (50·0%)
Kovacs et al (2005)10 Hungary 433 21 (4·7%) NA NA Mean 2·45 9/21 (42·8%) 2/21 (9·5%)
Neuhold et al (2001)11 Austria 118 10 (8·6%) 6/57 (10·5%) 4/61 (6·6%) Mean 4·9 0 3/10 (30·0%)
Data are n (%), unless otherwise indicated. NA=not available. *Tumour size was less than 3 mm in 15 (38%) cases.
Table 1: Prevalence and characteristics of occult papillary thyroid microcarcinomas at autopsy 
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and larger tumour size (>6 mm).41 Furthermore, the 
likelihood of lateral neck lymph node involvement was 
associated with extrathyroidal extension, multifocal 
lesions, central neck lymph node involvement, and 
location of the tumour in the upper third of the 
thyroid lobe.
Microscopic extrathyroidal extension, subcapsular 
location of the primary tumour, and multifocal disease 
have been associated with a higher risk of recurrence and 
locoregional metastases at diagnosis in some,36,40,44–46 but 
not all studies.47–51 Results from other studies have 
suggested that the risk factors associated with recurrence 
might diﬀ er between younger (<45 years at diagnosis) and 
older patients.52 In a recent meta-analysis, clinical 
recurrences were associated with multifocal tumours, 
locoregional metastases at diagnosis, and younger age, but 
not with sex, size of the primary tumour, or extrathyroidal 
extension.53 Buﬀ et and colleagues40 proposed a scoring 
system to predict recurrences in papillary thyroid 
microcarcinoma that relies on histo logical features, 
including tumour multifocality, extrathyroidal extension, 
and lymph node involvement. The negative eﬀ ect of N1 (ie, 
neck lymph node metastases) should not be overestimated. 
Among patients with N1 disease, the size and number of 
metastatic lymph nodes as well as the presence or absence 
of extracapsular extension should be taken into account to 
assess the eﬀ ect of N1 on the risk of relapse.54–56 In the 2015 
American Thyroid Association (ATA) guidelines, patients 
with N1 disease were classiﬁ ed as low, intermediate, or 
high risk on the basis of the number and size of N1, 
whereas in the 2009 ATA classiﬁ cation, all patients with 
neck lymph node metastases were classiﬁ ed as 
intermediate risk.55,57
Potential histological and biological prognostic factors 
(including mutation status) have been analysed. 
Desmoplastic stromal reaction is associated with lymph 
node metastases and histological invasive features such 
as peritumoral inﬁ ltration and vascular invasion.58 
Furthermore, an inﬁ ltrative growth pattern of the 
primary tumour and tumour-associated ﬁ brosis is 
signiﬁ cantly associated with locoregional lymph node 
involvement at diagnosis.59 In a clinicopathological study 
of 60 patients with papillary thyroid microcarcinoma, 
multivariate analysis showed peritumoural lymphatic 
vessel density as the only independent variable associated 
with a higher rate of locoregional neck metastases.60
A combination of tumour size and maximum 
standardised uptake value of the primary tumour on 
¹⁸F-FDG PET scanning has been shown to predict the 
likelihood of central neck lymph node metastasis from 
papillary thyroid microcarcinoma with a sensitivity of 68% 
and a speciﬁ city of 71%.61 In another study, researchers 
showed the absence of correlation between ¹⁸F-FDG 
uptake and BRAF mutation in papillary thyroid 
microcarcinoma.62 However, even when multiple clinical 
factors are combined, the speciﬁ city and positive predictive 
value of these models are too poor to provide useful 
preoperative risk stratiﬁ cation.63 Furthermore, many of the 
potentially important risk factors can only be determined 
postoperatively on the basis of thyroid pathology.
BRAF mutations are present in 30–67% of patients 
with papillary thyroid microcarcinomas64–75 and are 
associated with locoregional metastases, extrathyroidal 
extension, and an increased American Joint Committee 
on Cancer (AJCC) stage at presentation.67,68,72,74,76,77 In a 
meta-analysis of data from 2247 patients with papillary 
thyroid microcarcinoma, an increased risk of recurrence 
was reported in those with a BRAF mutation 
(odds ratio 2·09 [95% CI 1·31–3·33]; p=0·002).78 The 
histopathological and molecular proﬁ les (BRAF, RAS) of 
papillary thyroid microcarcinoma were studied in a 
cohort of 29 patients with locoregional metastases and 
compared with a cohort of 30 patients matched for age, 
sex, and tumour size, but with papillary thyroid 
microcarcinoma conﬁ ned to the thyroid.46 Tumours with 
locoregional metastases were more likely to have 
extrathyroidal extension, inﬁ ltrative borders, multiple 
foci, and to harbour a BRAF mutation. Additionally, a 
subcapsular location of the tumour was also associated 
with nodal metastases. A predictive score that 
incorporated three histological features (superﬁ cial 
tumour location, intraglandular spread or multifocality, 
and tumour ﬁ brosis) with BRAF status was more 
predictive of locoregional spread than BRAF status or the 
histological characteristics alone. However, this score has 
limited applicability to the selection of patients for active 
surveillance, since two of the variables (multifocality and 
tumour ﬁ brosis) can only be assessed postoperatively.
TERT promoter mutations are present in fewer than 
10% of patients with papillary thyroid microcarcinoma,79,80 
with some studies showing a correlation between TERT 
promoter mutation and aggressive clinicohistological 
features. Recently, the association of BRAF and TERT 
Number of 
patients
Follow-up 
(years)
Palpable lymph 
nodes, n (%)
Relapse, n 
(%)
Thyroid cancer-
related death, n (%)
Baudin et al (1998)31 281 7·3 89 (31·6%) 11 (3·9%) 0
Yamashita et al (1999)32 1743 11·2 90 (5·2%) 31 (1·8%) 4 (0·2%)
Wada et al (2003)33 259 5·2 24 (9·3%) 6 (2·3%)* 0
Pelizzo et al (2006)34 403 8·5 NA 6 (1·5%) 1 (0·2%)
Ito et al (2007)35 317 8·9 0 7 (2·2%) 0
Hay et al (2008)36 900 17·2 131 (14·6%) 5·7%† 3 (0·3%)
Noguchi et al (2008)37 2070 15·1 NA 73 (3·5%) 2 (0·2%)
Besic et al (2009)38 254 4·7 51 (20·1%) 7 (2·7%) 0
Moon et al (2011)39 288 6·0 NA 12 (4·2%) 0
Buﬀ et et al (2012)40 1668 6·5 NA 68 (4·1%) 0
Zhang et al (2012)41 1066 2·7 99 (9·3%) 10 (0·9%) 0
Studies shown included more than 250 patients with papillary thyroid microcarcinoma. *Rate of recurrence: four 
(16·7%) of 24 patients in the presence of palpable lymph nodes, two (0·4%) of 235 patients in the absence of palpable 
lymph nodes. †At 20 years. NA=not available.
Table 2: Frequency of relapse and thyroid cancer-related mortality in patients with papillary thyroid 
microcarcinoma
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promoter mutations present in 22 (3%) of 653 patients 
with papillary thyroid cancers was associated with 
clinicopathological features of high-risk diﬀ erentiated 
thyroid cancer, including older age, larger tumour size, 
extrathyroidal invasion, capsular invasion, and advanced 
disease stages.80
The presence of multiple mutations within the same 
papillary thyroid microcarcinoma (BRAF and TERT or 
multiple mutations) is rare and might predict a more 
aggressive disease.80,81 However, this hypothesis needs to 
be conﬁ rmed in prospective clinical studies. A more 
comprehensive, integrated assessment of the genome by 
next-generation sequencing might identify a gene 
signature in aggressive papillary thyroid microcarcinoma.
Indications for ﬁ ne needle aspiration
Thyroid nodules smaller than 1 cm in diameter that are 
highly suspected to be papillary thyroid microcarcinomas 
on the basis of neck ultrasonography that should be 
submitted to ﬁ ne needle aspiration biopsy are those for 
which, if malignancy is conﬁ rmed, a resection will be 
preferred to active surveillance because of ultra-
sonographic features suggesting a high risk of 
recurrence—ie, thyroid nodules with the presence of 
cervical lymph node metastases, extrathyroidal extension, 
or multiple foci. Thyroid incidentalomas detected by 
¹⁸F-FDG PET that are smaller than 1 cm in diameter and 
have ultrasound criteria of malignancy could also beneﬁ t 
from ﬁ ne needle aspiration biopsy in rare cases in which 
the diagnosis of intrathyroid metastases aﬀ ects the 
treatment of the other primary cancer. Additionally, 
suspicious subcentimetre nodules in subcapsular 
locations where even minor disease progression could be 
associated with complications (eg, adjacent to recurrent 
laryngeal nerve or trachea) should also be considered for 
biopsy.82 The exclusion of patients with these nodules 
from active surveillance is mainly based on the absence of 
data, because these patients were not oﬀ ered surveillance 
in the study by Ito and colleagues.82 If active surveillance 
is chosen for these nodules, it should be done within the 
frame of prospective trials, since treatment de-escalation 
should be a prudent process. There is, however, a concern 
about the level and availability of expertise and experience 
needed to accurately recognise the presence of 
extrathyroid extension, multifocality, and at-risk nodules 
on neck ultrasonography because of their location. 
Otherwise, thyroid nodules smaller than 1 cm in size 
should not be submitted to ﬁ ne needle aspiration biopsy. 
This recommendation is unanimous, and is considered a 
strong recommendation with moderate quality of 
evidence in the 2015 ATA guidelines.55,83
Initial treatment
Surgery 
In patients with clinical lymph node metastases (cN1), 
surgery is the standard treatment. In most cases the 
clinical lymph nodes are located in the lateral 
compartment. A total thyroidectomy with therapeutic 
central and lateral lymph node dissection is then 
recommended because lateral neck metastases are present 
in 83% of patients with papillary thyroid microcarcinoma, 
central neck metastases in 96%, and skip metastases 
(lateral neck metastases without central neck metastases) 
in only 4%.33,55 Because the eﬀ ects of neck dissection on 
survival have not been clearly shown and because of the 
morbidity of surgery, even in high-volume centres, the 
extent of prophylactic central neck dissections done in 
conjunction with a therapeutic lateral neck dissection 
remains controversial. Some centres will recommend a 
bilateral prophylactic central neck dissection, others a 
unilateral, and less frequently no central prophylactic 
neck dissection at all. The same uncertainties exist 
regarding the prophylactic contra lateral neck dissection.
In the absence of clinical lymph node involvement (cN0), 
the low risk of recurrence of papillary thyroid 
microcarcinoma has to be taken into account and balanced 
against the risk of permanent complications of total 
thyroidectomy and the possibility of salvage therapy in 
case of recurrence. The risk of recurrence is similar after 
lobectomy and total thyroidectomy in patients with 
unifocal papillary thyroid microcarcinoma without 
extrathyroid extension and cN0. Permanent compli cations 
of thyroid surgery include permanent hypo parathyroidism 
and recurrent nerve palsy and can be decreased if surgery 
is done by highly experienced surgeons.84,85 However, even 
for operations done by experienced surgeons, the risk of 
permanent hypoparathyroidism and permanent recurrent 
nerve palsy is 1–3% following total thyroidectomy and 
prophylactic neck dissection, higher than following a total 
thyroidectomy alone or a lobectomy, for which it is less 
than 1%.  The main advantage of a lobectomy is that it 
carries no risk of permanent hypocalcaemia, by contrast 
with a total thyroidectomy.86
In view of these data, thyroid lobectomy alone is a 
suﬃ  cient treatment for unifocal, intrathyroidal, and cN0 
papillary thyroid microcarcinoma in the absence of 
previous head and neck radiation, familial thyroid 
carcinoma, and abnormalities of the contralateral thyroid 
lobe.55 Furthermore, following lobectomy, not all patients 
will need levothyroxine treatment since overt 
hypothyroidism will occur in only 22% of cases.87 Finally, 
quality of life is preserved in most, but not all, patients 
receiving levothyroxine treatment.88 The drawback is that 
follow-up of patients might seem more convenient after 
a total thyroidectomy compared with a lobectomy. 
However, recent data show that serum thyroglobulin 
concentrations can be easily used to assess patient 
response after a lobectomy.89
Radioactive iodine
The question of whether to use radioactive iodine 
ablation following a diagnosis of papillary thyroid 
microcarcinoma only concerns patients who undergo 
total thyroidectomy. In patients with unifocal papillary 
www.thelancet.com/diabetes-endocrinology   Published online August 19, 2016   http://dx.doi.org/10.1016/S2213-8587(16)30180-2 5
Review
thyroid microcarcinoma and in the absence of lymph 
node metastases, there is no indication for postoperative 
remnant ablation as recommended by the 2009 and 2015 
ATA guidelines and by the 2006 European guidelines.55,57,90 
In patients with multifocal tumours, a risk factor for 
recurrence, the ATA guidelines do not recommend 
routine radioactive iodine ablation. Finally, in patients 
with extrathyroid extension of papillary thyroid 
microcarcinoma—another risk factor for recurrence—
the role of radioactive iodine ablation is controversial, 
and the beneﬁ t of this treatment on recurrence-free 
survival has not been shown.
Follow-up 
The frequency of follow-up of patients with papillary 
thyroid microcarcinoma has to be adapted to the indolent 
course of the disease and to its low level of recurrence. 
Recurrence can be diagnosed by measurement of thyro-
globulin concentration or neck ultrasonography. Following 
total thyroidectomy without radioactive iodine 
administration, serum thyroglobulin concentrations are 
dependent on the amount of thyroid residue left by the 
surgeon. In expert hands, serum thyroglobulin con-
centration is expected to be lower than 1 ng/mL in 96% of 
patients and lower than 2 ng/mL in all patients after total 
thyroidectomy.91,92 Thyroglobulin antibodies, initially 
present in 10–20% of patients, are expected to decrease 
spontaneously.92 Following lobectomy, thyroglobulin 
concentration, and trends in thyroglobulin concentrations 
and thyroglobulin antibodies over time, can be taken into 
account to deﬁ ne an excellent response, with a value of less 
than 30 ng/mL as a cutoﬀ  for thyroglobulin concentration.89
The remaining question is the frequency at which these 
examinations should be done. Unfortunately, prospective 
clinical data are not available. Thyroglobulin measurement 
and neck ultrasonography are done at 6–12 months after 
initial treatment. In the absence of abnormality, serum 
thyroglobulin measurement every 2–4 years seems 
reasonable, and in patients treated with lobectomy a neck 
ultrasonography every 4–5 years seems reasonable. 
Because of the absence of evidence, this follow-up strategy 
of surveillance is a proposition and can only be debated 
until further convincing data become available.
Active surveillance: an alternative to surgery 
Active surveillance is a strategy initially used in the 
setting of low-risk localised prostate cancer. It is an 
approach with a curative intent in which active treatment 
is delayed until the cancer shows signiﬁ cant progression 
to avoid (or at least delay) side-eﬀ ects of treatment.93 
This strategy can only be used in patients with indolent 
malignancies. Active surveillance is a new management 
strategy in oncology for both physicians and patients. 
As a result, both need to be made aware of and educated 
about the approach, and physicians need to gain 
experience of it, especially since patients are heavily 
inﬂ uenced by physicians in their decision of whether or 
not to opt for active surveillance.94 Furthermore, the 
eﬀ ects of anxiety created by the diagnosis of cancer 
without receiving active treatment need to be assessed 
and investigated, and might change with time.95 
Although the general concept that very low-risk thyroid 
cancer can be safely observed without immediate 
treatment is slowly being accepted by patients and 
physicians, much more experience will be required 
before this approach will be widely applied in routine 
clinical practice.
Patients with papillary thyroid microcarcinoma who 
meet the following criteria are good candidates for active 
Figure 1: Ultrasound images of patients with papillary thyroid 
microcarcinoma showing suitability for active surveillance
(A) Suitable for active surveillance because the papillary thyroid microcarcinoma 
is conﬁ ned to the thyroid parenchyma. (B) Not suitable for active surveillance 
because of location close to the thyroid capsule (arrow); the limits of the thyroid 
microcarcinoma are shown by the two As. (C) Not suitable for active surveillance 
because of location close to the trachea  (arrow is pointing to the thyroid capsule 
close to the trachea).  
A A
+ +
A
C
B
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surveillance: tumour size of 1 cm or less, conﬁ ned to the 
thyroid parenchyma, not adjacent to the thyroid capsule, 
or in the absence of abnormal cervical lymph nodes or 
recurrent nerve palsy (ﬁ gure 1).96,97 Many factors can 
aﬀ ect the decision for or against active surveillance.96 
These factors include patient characteristics such as age, 
family history of thyroid cancer, compliance with follow-
up, and willingness to defer immediate surgery (ﬁ gure 2); 
and characteristics of the multidisciplinary team such as 
the experience of the clinician treating the thyroid cancer 
and the quality of neck ultrasonography.96 However, the 
level of clinician experience is diﬃ  cult to assess because 
criteria to deﬁ ne relevant expertise are not available.
So far, all studies of active surveillance in patients 
with papillary thyroid microcarcinoma have been 
done in Japan.43,82,97,98,100 The active surveillance 
programme consisted of serial neck ultrasonography 
every 6–12 months. Signiﬁ cant progression of the 
primary tumour was deﬁ ned as an increase in size of 
3 mm or more, or identiﬁ cation of locoregional or 
distant metastases. The ﬁ rst report on a cohort of 340 
patients managed with active surveillance showed that 
22 (6%) patients with papillary thyroid microcarcinoma 
had an increase in tumour size (≥3 mm) at 5 years and 
54 (16%) had an increase at 10 years.82 Only seven (1%) 
patients developed locoregional lymph node metastases.82 
No patients developed distant metastases, and no 
disease-speciﬁ c deaths were reported.82 The update of 
this prospective cohort study included 1235 patients with 
papillary thyroid microcarcinoma followed up for more 
than 1·5 years (mean follow-up 5 years).100 Consistent 
with the initial ﬁ ndings, 58 (5%) patients showed an 
increase in tumour size during follow-up (ie, an increase 
of ≥3 mm or a tumour size of ≥12 mm), 19 (2%) had 
locoregional lymph node metastases (mostly located in 
the lateral compartment), and no patients developed 
distant metastases (table 3).100 All patients who 
underwent surgery at the time of progression had a 
favourable outcome, similar to the outcome seen in 
patients who had immediate surgery. Furthermore, 
patients undergoing active surveillance had a lower 
frequency of unfavourable events such as permanent 
hypoparathyroidism than those who had immediate 
surgery (0·8% vs 1·6%, respectively; p=0·0001).43 Finally, 
no thyroid cancer-related deaths were reported in 
patients under active surveillance or in patients treated 
with surgery during the same time period at the same 
institution.
Age is the only identiﬁ ed risk factor for disease 
progression, with younger patients (aged <40 years) 
being more likely to progress than older patients 
(table 3).100 Tumour size, multiple foci, sex, thyroid-
stimulating hormone concentration, and family history 
were not signiﬁ cant prognostic factors for progression.100 
Disease progression was noted in four of nine patients 
with papillary thyroid microcarcinoma under observation 
during pregnancy.101 However, an updated assessment 
showed disease progression in only four (8%) of 
50 patients with papillary thyroid microcarcinoma 
examined before and after a full-term pregnancy.102 
Findings from a recent study suggested that changes in 
ultrasonographic pattern during follow-up might predict 
progression, with consolidation of calciﬁ cation and loss 
of vascularity during follow-up being signiﬁ cant 
indicators for non-progressive disease.103
These data suggest that a long-term active surveillance 
management approach might be more eﬀ ective and 
appropriate in older patients than in younger patients. 
However, younger patients could also opt for an active 
surveillance approach for deferral of surgical 
intervention to a more convenient time. The drawback 
of active surveillance is its acceptance by patients. 
Indeed, half of patients from the centre that initiated 
the approach in thyroid cancer and promoted it through 
a prospective trial chose immediate surgery rather than 
surveillance.43
Other than age, there is no identiﬁ ed predictor of 
progression of papillary thyroid microcarcinoma during 
active surveillance. Whether the molecular proﬁ ling of 
papillary thyroid microcarcinoma can be useful to decide 
whether active surveillance can be oﬀ ered is a question 
that needs to be answered. A large genomic analysis 
might be more pertinent than an analysis focusing on 
BRAF and TERT mutations. In view of the indolent 
natural history of papillary thyroid microcarcinomas, the 
question of the cost-eﬀ ectiveness of active surveillance 
will also have to be addressed.Figure 2: Decision tree for treatment of patients with papillary thyroid microcarcinoma
Yes No
Family history of thyroid cancer or previous 
head and neck external beam radiation
Papillary thyroid microcarcinoma or thyroid 
nodule ≤1 cm with high-suspicion 
ultrasonographic features
Suspicion of one or more of the following:
• Extrathyroid extension
• Papillary thyroid microcarcinoma adjacent 
 to recurrent laryngeal nerve or to trachea
• Metastatic lymph node on neck ultrasound
• Multinodular thyroid
Yes No
Consider active surveillance, (especially in 
patients aged >40 years) with neck 
ultrasonography every 6–12 months
Consider surgery after ﬁne needle 
aspiration biopsy
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All data for active surveillance have been obtained in 
Japan and conﬁ rmation by prospective trials in North 
America and Europe are needed. However, on the basis of 
these data and a careful consideration of the risks versus 
beneﬁ ts of immediate surgical intervention in papillary 
thyroid microcarcinoma, the authors of the 2015 ATA 
guidelines note that, although surgery is generally 
recommended for cytologically conﬁ rmed thyroid cancer, 
an active surveillance management approach “can be 
considered” as an alternative to immediate surgery in 
patients with very low-risk tumours, such as papillary 
microcarcinomas without other known high-risk clinical, 
cytological, or molecular (if assessed) features.55 An 
eﬀ ective active surveillance management plan requires 
careful patient selection, meticulous neck ultrasound 
follow-up, and a shared treatment philosophy between the 
patient and all members of the disease management team. 
The optimum patient for active surveillance is an older 
patient (>40 years) with a unifocal papillary microcarcinoma 
with no ultrasound evidence of extrathyroidal extension or 
cervical lymph node involvement in the setting of an 
otherwise normal thyroid ultrasound, and who is willing to 
return at 6–12-month intervals for serial ultrasound 
examinations over many years.
Local destruction: an alternative to surgery? 
Radiofrequency ablation, ethanol injection, and laser 
ablation were ﬁ rst developed for the treatment of distant 
metastases from thyroid cancer, locoregional recurrences 
of thyroid cancer, and benign nodules.104,105 Treatment of 
papillary thyroid microcarcinomas with these techniques 
has been little studied. Recent reports of needle track 
tumour seeding after radiofrequency ablation of a thyroid 
cancer and incomplete destruction of a thyroid cancer 
should lead to a prospective assessment of these 
techniques.106,107 A feasibility study in three patients treated 
with laser ablation followed by surgery was recently 
reported.108 The primary papillary thyroid microcarcinomas 
were destroyed, leaving the problems of multifocality and 
perithyroid metastatic lymph nodes. These results 
emphasise the question of whether papillary thyroid 
microcarcinomas need treatment or not.
Conclusions 
To address recent concerns regarding overdiagnosis and 
overtreatment of papillary thyroid microcarcinomas, an 
active surveillance approach in which active treatment is 
delayed until the cancer shows signs of substantial 
progression should be considered in selected patients. 
Criteria for selection include the absence of clinical 
lymph node metastases, absence of ultrasound signs of 
extrathyroid extension, and location of the nodule distant 
from the recurrent laryngeal nerve or trachea. Available 
data suggest the safety of active surveillance, but further 
prospective data from the USA and Europe are needed. 
The drawbacks of active surveillance are its poor 
acceptance by patients and the need for frequent follow-
up. A renaming of the term papillary thyroid 
microcarcinoma to indolent lesion of epithelial origin 
will not solve all problems because we will still need to 
identify the few lesions that will progress and need 
surgery. In this context, genomic analysis should be 
investigated for its ability to determine which patients 
with papillary thyroid microcarcinoma require surgery 
and those who do not need follow-up. 
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